Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4454 Target Snapshot

Tyrosine-protein kinase Fgr · SINGLE PROTEIN · Homo sapiens

1,154Compounds
347Assays
23Approved Drugs
354.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P09769. Use UniProt P09769 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P09769 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Fgr as ChEMBL target CHEMBL4454, mapped to UniProt P09769. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Fgr
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4454
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09769
Tyrosine-protein kinase Fgr
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Fgr is the right protein anchor across sources, using UniProt P09769 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase Fgr
UniProt AccessionP09769
Component TypeProtein
Sequence Length529 aa

Tyrosine-protein kinase Fgr

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Fgr, mapped to UniProt P09769. Sequence length is 529 aa.

Mapped IDP09769
Review nameTyrosine-protein kinase Fgr
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

23
Approved
7
Phase III
10
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50129.0
KI2.0
EC501.0
KD222.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL249097 9.52 Kd 0.3 Preclinical
CHEMBL3647967 9.4 IC50 0.4 Preclinical
CHEMBL5416410 9.3 Kd 0.5 Approved
CHEMBL388978 9.18 IC50 0.658 Preclinical
CHEMBL364623 9.1 IC50 0.8 Preclinical
CHEMBL288441 8.96 IC50 1.1 Approved
CHEMBL1873475 8.74 IC50 1.82 Approved
CHEMBL2151321 8.66 IC50 2.2 Preclinical
CHEMBL386051 8.62 Kd 2.4 Preclinical
CHEMBL2336005 8.43 IC50 3.7 Preclinical
Distribution

pChEMBL Value Distribution

14
5.0
27
5.5
30
6.0
29
6.5
27
7.0
11
7.5
8
8.0
8
8.5
7
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
IBRUTINIB
CHEMBL1873475
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
CRIZOTINIB
CHEMBL601719
Approved 2011
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

347
Total Assays
133
Tested Compounds
2
Assay Types
Binding — 346 assays, 133 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 285 112 6.7
assay format 32 1 4.6
cell-based format 22 12 6.0
subcellular format 6 7 6.5
cell membrane format 1 1 8.4
ADME — 1 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 2 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine